SCHEMBL16829633

SCHEMBL16829633

CS(=O)(=O)CCCOc1cc(C(F)(F)F)ccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.42
NOS2 P35228 1/20 0.42
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
ALDH1A1 P00352 2/20 0.38
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SCN9A Q15858 2/20 0.37
SCN10A Q9Y5Y9 1/20 0.37
MKNK1 Q9BUB5 6/20 0.36
NPC1 O15118 1/20 0.36
CASP3 P42574 1/20 0.36
RAB9A P51151 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
HTR1A P08908 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NR2E1 Q9Y466 1/20 0.35
ADRB2 P07550 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29423940 1.00 NOS3 (0.42) NOS3NOS2CYP11B1CYP11B2ALDH1A1
SCHEMBL15471437 0.79 NOS3 (0.46) NOS3NOS2ALDH1A1GAAL3MBTL1
SCHEMBL29423932 0.77 NOS3 (0.41) NOS3NOS2ALDH1A1GAAL3MBTL1
SCHEMBL16829687 0.77 NOS3 (0.41) NOS3NOS2ALDH1A1GAAL3MBTL1
SCHEMBL15465000 0.75 ADRB2 (0.41) NOS3NOS2ALDH1A1GAAL3MBTL1
SCHEMBL19732851 0.75 NOS3 (0.50) NOS3NOS2ALDH1A1GAAL3MBTL1
SCHEMBL3021877 0.75 NOS3 (0.46) NOS3NOS2CYP11B1CYP11B2ALDH1A1
SCHEMBL15465117 0.75 ALDH1A1 (0.44) ALDH1A1GAAL3MBTL1HTR1ANR2E1
SCHEMBL3149643 0.75 NOS3 (0.48) NOS3NOS2ALDH1A1GAAL3MBTL1
SCHEMBL28746485 0.75 L3MBTL1 (0.43) NOS3NOS2ALDH1A1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3974413-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2022-03-30 EP disclosed
EP-3082786-B1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME (US) 2021-10-27 EP disclosed
US-9834563-B2 Antidiabetic substituted heteroaryl compounds MERCK SHARP & DOHME CORP. (US) 2017-12-05 US disclosed
US-20170166578-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME LLC 2017-06-15 US disclosed
EP-3082786-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS Merck Sharp & Dohme Corp. (US) 2016-10-26 EP disclosed
WO-2015095256-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2015-06-25 WO disclosed
WO-2015089809-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2015-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166578-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS GPR119, GPR65, GPR55 NOS3 3035/4885NOS2 2915/4885CYP11B1 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.